Clinical trials in Meldola – page 21

439 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Meldola at a glance

439

clinical trials

Paediatric trials0
Research sites1

Quick filters

439 trials in Meldola

Open in trial search

Non-small cell lung cancer recurrent+1

Not recruiting

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Amgen Inc.

Contact Research Centre

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Breast cancer+3

Not recruiting

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

InvestigationalNo placebo

Study of BT8009 for Patients with Advanced Breast Cancer with NECTIN4 Amplification

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:ZELENECTIDE PEVEDOTIN
Sponsor:Bicycletx Limited

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Registered drugNo placebo

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Pfizer Inc.

Contact Research Centre

Primary myelofibrosis

Not recruiting

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Luspatercept
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Endometrial cancer+4

Not recruiting

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Raludotatug Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

Registered drugNo placebo

Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anhydrous Docetaxel
Sponsor:iOnctura SA

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Acasunlimab
Sponsor:Genmab A/S

Contact Research Centre

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:IRCCS Ospedale Policlinico San Martino

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

Advanced treatments for diffuse large B-cell lymphoma
Multiple myeloma therapies for transplant-ineligible patients
Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

Targeted therapies for metastatic colorectal cancer
Novel combinations for advanced NSCLC
Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

Advanced treatments for metastatic prostate cancer
Maintenance therapy in urothelial cancer
Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to Italy All countries